DelveInsight’s, “Ewing Sarcoma Pipeline Insights 2023” report provides comprehensive insights about 25+ Ewing Sarcoma companies and 25+ pipeline drugs in the Ewing Sarcoma pipeline landscape. It covers the Ewing Sarcoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Ewing Sarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Ewing Sarcoma Pipeline Report

• DelveInsight’s Ewing Sarcoma pipeline report depicts a robust space with 25+ Ewing Sarcoma companies working to develop 25+ pipeline therapies for Ewing Sarcoma treatment.
• The leading Ewing Sarcoma Companies working in the market include Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Promising Ewing Sarcoma Pipeline Therapies in the various stages of development includes Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.
• December 2023: St. Jude Children’s Research Hospital announced a study of Phase 1 & 2 clinical trials for Onivyde, Talazoparib and Temozolomide. The phase I portion of this study is designed for children or adolescents and young adults (AYA) with a diagnosis of a solid tumor that has recurred (come back after treatment) or is refractory (never completely went away). The trial will test 2 combinations of therapy and participants will be randomly assigned to either Arm A or Arm B. The purpose of the phase I study is to determine the highest tolerable doses of the combinations of treatment given in each Arm.
• December 2023: Children’s Hospital of Philadelphia announced a study of Phase 1 clinical trials for Cabozantinib. The purpose of this study is to better understand how safe and effective the drug cabozantinib in combination with high-dose ifosfamide is in the treatment of children and adults with relapsed/refractory Ewing sarcoma and osteosarcoma.
• December 2023: Fusion Pharmaceuticals Inc. announced a study of Phase 1 clinical trials for [225]-FPI-2059 and [111In]-FPI-2058. This is a first-in-human Phase 1 clinical trial designed to investigate the safety, tolerability, pharmacokinetics, and biodistribution of [225Ac]-FPI-2059 and [111In]-FPI-2058 in participants with neurotensin receptor 1 (NTSR1)-expressing solid tumours.

 

Request a sample and discover the recent advances in Ewing Sarcoma Treatment Drugs @ Ewing Sarcoma Pipeline Outlook Report

 

The Ewing Sarcoma pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Ewing Sarcoma drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Ewing Sarcoma clinical trial landscape.

 

Ewing Sarcoma Overview

Ewing sarcoma is the second most common primary malignant bone tumor, mostly affecting adolescents in the second decade of their life, and it is a highly metastatic class of sarcoma. Despite the use of radiotherapy or surgery, historically, an estimated 85% to 90% of patients died within a few months from a metastasis.

 

Find out more about Ewing Sarcoma Treatment Landscape @ Drugs for Ewing Sarcoma Treatment

 

Ewing Sarcoma Emerging Drugs Profile

• Vigil: Gradalis
• ONCT216: Oncternal Therapeutics
• SP-2577: Salarius Pharmaceuticals

 

Ewing Sarcoma Pipeline Therapeutics Assessment

There are approx. 25+ Ewing Sarcoma companies which are developing the Ewing Sarcoma therapies. The Ewing Sarcoma companies which have their Ewing Sarcoma drug candidates in the most advanced stage, i.e. Phase III include, Gradalis.

 

DelveInsight’s Ewing Sarcoma pipeline report covers around 25+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Ewing Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

 

Ewing Sarcoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

 

Learn more about the emerging Ewing Sarcoma Pipeline Therapies @ Ewing Sarcoma Clinical Trials Assessment

 

Scope of the Ewing Sarcoma Pipeline Report

• Coverage- Global
• Ewing Sarcoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Ewing Sarcoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Ewing Sarcoma Companies- Gradalis, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, Tyme, Inc, Pfizer, Hutchison Medipharma Limited, Bristol-Myers Squibb, Salarius Pharmaceuticals, BioAtla, Inc., Cellectar Biosciences, Valent Technologies, Inhibrx, Inc., Eisai Co Ltd, Amgen, Y-mAbs Therapeutics, NanoValent Pharmaceuticals, Oncternal Therapeutics, Aptadel Therapeutics, Gibson Oncology, Edison Oncology, Oncoheroes Biosciences, CotheraBio, Rakovina Therapeutics, and others.
• Ewing Sarcoma Pipeline Therapies- Vigil, Temozolomide, Irinotecan, CP-751,871, Eribulin mesylate, Combination metyrosine-derivative, low-dose methoxsalen, phenytoin and sirolimus (MPS), TB-403 20mg/kg, Irinotecan, Temozolomide, exatecan mesylate, CP-751,871, plerixafor, and others.

 

Dive deep into rich insights for new drugs for Ewing Sarcoma treatment, Visit @ Ewing Sarcoma Market Drivers and Barriers, and Future Perspective

 

Table of Content

1. Introduction
2. Ewing Sarcoma Executive Summary
3. Ewing Sarcoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Ewing Sarcoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Vigil: Gradalis
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. ONCT216: Oncternal Therapeutics
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. SP-2577: Salarius Pharmaceuticals
15. Drug profiles in the detailed report…..
16. Early Stage Products (Phase I)
17. CLR 131: Cellectar Biosciences
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Ewing Sarcoma Companies
21. Ewing Sarcoma Key Products
22. Ewing Sarcoma Unmet Needs
23. Ewing Sarcoma Market Drivers and Barriers
24. Ewing Sarcoma Future Perspectives and Conclusion
25. Ewing Sarcoma Analyst Views
26. Ewing Sarcoma Key Companies
27. Appendix

 

For further information on the Ewing Sarcoma pipeline therapeutics, reach out to Ewing Sarcoma Unmet Needs and Analyst Views

 

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/adeno-associated-virus-vectors-in-gene-therapy-market